Movement disorders in 2016

Progress in Parkinson disease and other movement disorders

In the field of movement disorders, areas that have seen important advances in 2016 include the pathogenesis of Parkinson disease involving extra-CNS α-synuclein pathology, treatment of hyperkinetic disorders with novel dopamine-depleting drugs, and MRI-guided ultrasound surgery for the treatment of essential tremor.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Mechanism of action of VMAT2 inhibitors.

References

  1. 1

    Deweerdt, S. Parkinson's disease: 4 big questions. Nature 538, S17 (2016).

    CAS  Article  PubMed  Google Scholar 

  2. 2

    Thenganatt, M. A. & Jankovic, J. Parkinson disease subtypes. JAMA Neurol. 71, 499–504 (2014).

    Article  PubMed  Google Scholar 

  3. 3

    Marras, C. & Chaudhuri, K. R. Nonmotor features of Parkinson's disease subtypes. Mov. Disord. 31, 1095–1102 (2016).

    CAS  Article  PubMed  Google Scholar 

  4. 4

    Sampson, T. R. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 167, 1469–1480 (2016).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. 5

    Unger, M. M. et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Parkinsonism Relat. Disord. 32, 66–72 (2016).

    Article  PubMed  Google Scholar 

  6. 6

    Gibbons, C. H., Garcia, J., Wang, N., Shih, L. C. & Freeman, R. The diagnostic discrimination of cutaneous α-synuclein deposition in Parkinson disease. Neurology 87, 505–512 (2016).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. 7

    Deng, H. X. et al. Identification of TMEM230 mutations in familial Parkinson's disease. Nat. Genet. 48, 733–739 (2016).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. 8

    Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA 316, 40–50 (2016).

  9. 9

    Jankovic, J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin. Pharmacother. 17, 2461–2470 (2016).

    CAS  Article  PubMed  Google Scholar 

  10. 10

    Elias, W. J. et al. A randomized trial of focused ultrasound thalamotomy for essential tremor. N. Engl. J. Med. 375, 730–739 (2016).

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Joseph Jankovic.

Ethics declarations

Competing interests

J.J. has received research and/or training grants from the Michael J. Fox Foundation for Parkinson Research, the NIH, Neurocrine Biosciences, Prothena Biosciences and Teva Pharmaceuticals. He has served as a consultant or as an advisory committee member for Allergan, Pfizer and Teva Pharmaceuticals.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jankovic, J. Progress in Parkinson disease and other movement disorders. Nat Rev Neurol 13, 76–78 (2017). https://doi.org/10.1038/nrneurol.2016.204

Download citation

Further reading

Search

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing